Home › Companies › CARA THERAPEUTICS INC. › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and CARA THERAPEUTICS INC.’s Form 8-K, filed June 7, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 4, 2024: 6 items on CARA THERAPEUTICS INC.’s Form 8-K, filed June 7, 2024: 2 elected · 4 approved.
Significant dissent: 1 director (23.2% against); 1 say-on-pay vote (60.4% support).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2025-2026
Explore CARA THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are CARA THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 7, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Susan Shiff, Ph.D. | 20,753,354 | -- | -- | 6,256,188 | 12,814,548 | 77% | Elected | — |
| Elect Director: Helen M. Boudreau | 26,317,774 | -- | -- | 691,768 | 12,814,548 | 97% | Elected | — |
| 2. Approval, on a Non-Binding Advisory Basis, of the Compensation of the Company's Named Executive Officers | 16,277,985 | 10,660,228 | 71,329 | -- | 12,814,548 | 60% | Approved | — |
| 3. Ratification of the Selection of Independent Registered Public Accounting Firm | 39,560,082 | 188,261 | 75,747 | -- | 0 | 99.5% | Approved | — |
| 4. Increase the Authorized Shares of Common Stock | 36,799,337 | 2,931,128 | 93,625 | -- | 0 | 93% | Approved | — |
| 5. Series of Alternate Amendments to Effect a Reverse Stock Split and Effect a Proportionate Reduction in the Total Number of Authorized Shares of Common Stock | 37,402,816 | 2,269,731 | 151,543 | -- | 0 | 94% | Approved | — |
Source: CARA THERAPEUTICS INC., Form 8-K, filed with the SEC on June 7, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
120 asset managers disclosed a vote on at least one CARA THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: Election of the Board of Directors' two nominees for director to serve until the Company's 2027 Annual Meeting and until their successors are duly elected and qualified: Helen M. Boudreau
CARA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Helen M. Boudreau”): 26,317,774 for, 691,768 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 - Election of Directors Dr. Susan Shiff and Ms. Helen M. Boudreau were each elected to serve as a director of the Company's Board of Directors until the 2027 Annual Meeting of Stockholders and until their successor is duly elected or until their earlier resignation or removal, by the fol…”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 30 asset managers below reported 5,312,784 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,448,409 | 0 | 0 | 0 | For |
| BlackRock | 1,045,222 | 0 | 0 | 0 | For |
| Fidelity | 819,543 | 0 | 0 | 0 | For |
| Charles Schwab | 328,951 | 0 | 0 | 0 | For |
| Voya | 201,871 | 0 | 0 | 0 | For |
| Equitable | 174,048 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 77,774 | 0 | 0 | 0 | For |
| Lincoln Financial | 39,200 | 0 | 0 | 0 | For |
| Northern Trust | 22,810 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 21,084 | 0 | 0 | 0 | For |
| Pacific Life | 17,348 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 14,222 | 0 | 0 | 0 | For |
| John Hancock | 11,861 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 10,900 | 0 | 0 | 0 | For |
| Nationwide | 10,791 | 0 | 0 | 0 | For |
| Legg Mason | 10,463 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 9,986 | 0 | 0 | 0 | For |
| SEI | 9,400 | 0 | 0 | 0 | For |
| ProShares | 9,265 | 0 | 0 | 0 | For |
| DWS | 8,323 | 0 | 0 | 0 | For |
| Principal | 6,521 | 0 | 0 | 0 | For |
| State Street | 3,343 | 0 | 0 | 0 | For |
| Calvert | 3,311 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,330 | 0 | 0 | 0 | For |
| Morgan Stanley | 1,882 | 0 | 0 | 0 | For |
Showing the 25 largest of 30 asset managers. All 30 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
77% Majority: yes · of votes cast
Description as filed by funds: Election of the Board of Directors' two nominees for director to serve until the Company's 2027 Annual Meeting and until their successors are duly elected and qualified: Susan Shiff, Ph.D.
CARA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Susan Shiff, Ph.D.”): 20,753,354 for, 6,256,188 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 - Election of Directors Dr. Susan Shiff and Ms. Helen M. Boudreau were each elected to serve as a director of the Company's Board of Directors until the 2027 Annual Meeting of Stockholders and until their successor is duly elected or until their earlier resignation or removal, by the fol…”
Support: 77% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 30 asset managers below reported 3,517,523 for, 364 against, 1,761,952 withheld, 32,945 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,448,409 | 0 | 0 | 0 | For |
| BlackRock | 0 | 0 | 0 | 1,045,222 | Withhold |
| Fidelity | 660,449 | 0 | 0 | 159,094 | Mixed |
| Charles Schwab | 328,951 | 0 | 0 | 0 | For |
| Voya | 0 | 0 | 0 | 201,871 | Withhold |
| Equitable | 0 | 0 | 0 | 174,048 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 77,774 | Withhold |
| Lincoln Financial | 39,200 | 0 | 0 | 0 | For |
| Northern Trust | 22,810 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 0 | 0 | 21,084 | 0 | Abstain |
| Pacific Life | 0 | 0 | 0 | 17,348 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 14,222 | Withhold |
| John Hancock | 0 | 0 | 11,861 | 0 | Abstain |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 10,900 | Withhold |
| Nationwide | 0 | 0 | 0 | 10,791 | Withhold |
| Legg Mason | 0 | 0 | 0 | 10,463 | Withhold |
| Principal Exchange-Traded Funds | 0 | 0 | 0 | 9,986 | Withhold |
| SEI | 9,400 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 0 | 9,265 | Withhold |
| DWS | 0 | 0 | 0 | 8,323 | Withhold |
| Principal | 0 | 0 | 0 | 6,521 | Withhold |
| State Street | 3,343 | 0 | 0 | 0 | For |
| Calvert | 0 | 0 | 0 | 3,311 | Withhold |
| T. Rowe Price | 2,330 | 0 | 0 | 0 | For |
| Morgan Stanley | 0 | 0 | 0 | 1,882 | Withhold |
Showing the 25 largest of 30 asset managers. All 30 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
94% Approved · of votes cast
Description as filed by funds: Approval of a series of alternate amendments to the Company's Amended and Restated Certificate of Incorporation to effect, at the option of the Board of Directors, a reverse stock split of the Company's common stock at a reverse stock split ratio ranging from one-for-four (1:4) to one-for-twelve (1:12), inclusive, and a corresponding proportionate reduction in the total number of authorized shares of the Company's common stock, with the effectiveness of one of such amendments and the abandonment of the other amendments, or the abandonment of all amendments, to be determined by the Board of Directors prior to the date of the 2025 Annual Meeting of Stockholders.
CARA THERAPEUTICS INC.’s own tally for this item (“5. Series of Alternate Amendments to Effect a Reverse Stock Split and Effect a Proportionate Reduction in the Total Number of Authorized Shares of Common Stock”): 37,402,816 for, 2,269,731 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 5 – A Series of Alternate Amendments to Effect a Reverse Stock Split and Effect a Proportionate Reduction in the Total Number of Authorized Shares of Common Stock The stockholders approved series of alternate amendments to the Company's Amended and Restated Certificate of Incorporation…”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 30 asset managers below reported 5,312,784 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,448,409 | 0 | 0 | 0 | For |
| BlackRock | 1,045,222 | 0 | 0 | 0 | For |
| Fidelity | 819,543 | 0 | 0 | 0 | For |
| Charles Schwab | 328,951 | 0 | 0 | 0 | For |
| Voya | 201,871 | 0 | 0 | 0 | For |
| Equitable | 174,048 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 77,774 | 0 | 0 | 0 | For |
| Lincoln Financial | 39,200 | 0 | 0 | 0 | For |
| Northern Trust | 22,810 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 21,084 | 0 | 0 | 0 | For |
| Pacific Life | 17,348 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 14,222 | 0 | 0 | 0 | For |
| John Hancock | 11,861 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 10,900 | 0 | 0 | 0 | For |
| Nationwide | 10,791 | 0 | 0 | 0 | For |
| Legg Mason | 10,463 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 9,986 | 0 | 0 | 0 | For |
| SEI | 9,400 | 0 | 0 | 0 | For |
| ProShares | 9,265 | 0 | 0 | 0 | For |
| DWS | 8,323 | 0 | 0 | 0 | For |
| Principal | 6,521 | 0 | 0 | 0 | For |
| State Street | 3,343 | 0 | 0 | 0 | For |
| Calvert | 3,311 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,330 | 0 | 0 | 0 | For |
| Morgan Stanley | 1,882 | 0 | 0 | 0 | For |
Showing the 25 largest of 30 asset managers. All 30 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
93% Approved · of votes cast
Description as filed by funds: Approval of an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 shares to 200,000,000 shares.
CARA THERAPEUTICS INC.’s own tally for this item (“4. Increase the Authorized Shares of Common Stock”): 36,799,337 for, 2,931,128 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 4 – Increase the Authorized Shares of Common Stock The stockholders approved the amendment of the Company's Certificate of Incorporation to increase the authorized number of shares of common stock from 100,000,000 to 200,000,000, by the following votes:”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 30 asset managers below reported 5,153,690 for, 159,094 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,448,409 | 0 | 0 | 0 | For |
| BlackRock | 1,045,222 | 0 | 0 | 0 | For |
| Fidelity | 660,449 | 159,094 | 0 | 0 | Mixed |
| Charles Schwab | 328,951 | 0 | 0 | 0 | For |
| Voya | 201,871 | 0 | 0 | 0 | For |
| Equitable | 174,048 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 77,774 | 0 | 0 | 0 | For |
| Lincoln Financial | 39,200 | 0 | 0 | 0 | For |
| Northern Trust | 22,810 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 21,084 | 0 | 0 | 0 | For |
| Pacific Life | 17,348 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 14,222 | 0 | 0 | 0 | For |
| John Hancock | 11,861 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 10,900 | 0 | 0 | 0 | For |
| Nationwide | 10,791 | 0 | 0 | 0 | For |
| Legg Mason | 10,463 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 9,986 | 0 | 0 | 0 | For |
| SEI | 9,400 | 0 | 0 | 0 | For |
| ProShares | 9,265 | 0 | 0 | 0 | For |
| DWS | 8,323 | 0 | 0 | 0 | For |
| Principal | 6,521 | 0 | 0 | 0 | For |
| State Street | 3,343 | 0 | 0 | 0 | For |
| Calvert | 3,311 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,330 | 0 | 0 | 0 | For |
| Morgan Stanley | 1,882 | 0 | 0 | 0 | For |
Showing the 25 largest of 30 asset managers. All 30 are in the interactive database (link above).
Combines 8 wordings of this item as funds reported it.
60% Approved · of votes cast
Prior year: 77.7% for (June 1, 2023 meeting) ▼ 17.3 pts
Description as filed by funds: Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers.
CARA THERAPEUTICS INC.’s own tally for this item (“2. Approval, on a Non-Binding Advisory Basis, of the Compensation of the Company's Named Executive Officers”): 16,277,985 for, 10,660,228 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 - Approval, on a Non-Binding Advisory Basis, of the Compensation of the Company's Named Executive Officers The stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers, by the following votes:”
Support: 60% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,448,409 | 0 | 0 | 0 | For |
| BlackRock | 0 | 1,045,222 | 0 | 0 | Against |
| Fidelity | 0 | 819,543 | 0 | 0 | Against |
| Charles Schwab | 0 | 328,951 | 0 | 0 | Against |
| Voya | 0 | 201,871 | 0 | 0 | Against |
| Equitable | 0 | 174,048 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 0 | 77,774 | 0 | 0 | Against |
| Lincoln Financial | 39,200 | 0 | 0 | 0 | For |
| Northern Trust | 22,810 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 0 | 21,084 | 0 | 0 | Against |
| Pacific Life | 0 | 17,348 | 0 | 0 | Against |
| AIG/SunAmerica | 0 | 14,222 | 0 | 0 | Against |
| John Hancock | 0 | 11,861 | 0 | 0 | Against |
| Blackstone Alternative Investment Funds | 0 | 10,900 | 0 | 0 | Against |
| Nationwide | 0 | 10,791 | 0 | 0 | Against |
| Legg Mason | 0 | 10,463 | 0 | 0 | Against |
| Principal Exchange-Traded Funds | 0 | 9,986 | 0 | 0 | Against |
| SEI | 0 | 9,400 | 0 | 0 | Against |
| ProShares | 0 | 9,265 | 0 | 0 | Against |
| DWS | 0 | 8,323 | 0 | 0 | Against |
| Principal | 0 | 6,521 | 0 | 0 | Against |
| State Street | 3,343 | 0 | 0 | 0 | For |
| Calvert | 0 | 3,311 | 0 | 0 | Against |
| T. Rowe Price | 0 | 2,330 | 0 | 0 | Against |
| Morgan Stanley | 0 | 1,882 | 0 | 0 | Against |
Fund voting reports, all 29 managers: 2,515,262 for, 2,797,158 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Chescapmanager LLC | 1,702,089 | 0 | 0 | 0 | For |
| DISCIPLINED GROWTH INVESTORS INC /MN | 0 | 1,600,555 | 0 | 0 | Against |
| BlackRock | 15,082 | 1,529,954 | 0 | 0 | Against |
| FARALLON CAPITAL MANAGEMENT LLC | 0 | 1,112,688 | 0 | 0 | Against |
| STIFEL NICOLAUS & CO INC \MO\ | 0 | 844,852 | 0 | 0 | Against |
| Two Sigma | 0 | 750,947 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 717,399 | 0 | 0 | Against |
| State Street | 666,734 | 3,362 | 0 | 0 | For |
| Renaissance | 0 | 340,753 | 0 | 0 | Against |
| Charles Schwab | 0 | 328,951 | 0 | 0 | Against |
| Northern Trust | 201,903 | 0 | 0 | 0 | For |
| Voya | 0 | 201,871 | 0 | 0 | Against |
| MELLON INVESTMENTS Corp | 0 | 184,640 | 0 | 0 | Against |
| Fidelity | 0 | 168,848 | 0 | 0 | Against |
| AllianceBernstein | 0 | 87,320 | 0 | 0 | Against |
| DE Shaw | 0 | 77,464 | 0 | 0 | Against |
| Ensign Peak Advisors, Inc | 54,897 | 0 | 0 | 0 | For |
| Vanguard | 38,706 | 0 | 0 | 0 | For |
| Rhumbline | 0 | 25,429 | 0 | 0 | Against |
| Fidelis Capital Partners, LLC | 0 | 25,403 | 0 | 0 | Against |
| Goldman Sachs | 131 | 25,031 | 0 | 0 | Against |
| WASHINGTON STATE INVESTMENT BOARD | 0 | 22,032 | 0 | 0 | Against |
| MACKENZIE FINANCIAL CORP | 0 | 21,176 | 0 | 0 | Against |
| Fisher Asset Management, LLC | 0 | 20,327 | 0 | 0 | Against |
| JPMorgan | 0 | 18,874 | 0 | 0 | Against |
Institutional-manager reports, all 100 managers: 2,712,166 for, 8,303,493 against, 14 abstained, 0 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.5% Approved · of votes cast
Prior year: 99.6% for (June 1, 2023 meeting) ▼ 0.1 pts
Description as filed by funds: Ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.
CARA THERAPEUTICS INC.’s own tally for this item (“3. Ratification of the Selection of Independent Registered Public Accounting Firm”): 39,560,082 for, 188,261 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3 - Ratification of the Selection of Independent Registered Public Accounting Firm The stockholders ratified the selection by the Audit Committee of the Board of Directors of the Company of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending…”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 30 asset managers below reported 5,312,784 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,448,409 | 0 | 0 | 0 | For |
| BlackRock | 1,045,222 | 0 | 0 | 0 | For |
| Fidelity | 819,543 | 0 | 0 | 0 | For |
| Charles Schwab | 328,951 | 0 | 0 | 0 | For |
| Voya | 201,871 | 0 | 0 | 0 | For |
| Equitable | 174,048 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 77,774 | 0 | 0 | 0 | For |
| Lincoln Financial | 39,200 | 0 | 0 | 0 | For |
| Northern Trust | 22,810 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 21,084 | 0 | 0 | 0 | For |
| Pacific Life | 17,348 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 14,222 | 0 | 0 | 0 | For |
| John Hancock | 11,861 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 10,900 | 0 | 0 | 0 | For |
| Nationwide | 10,791 | 0 | 0 | 0 | For |
| Legg Mason | 10,463 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 9,986 | 0 | 0 | 0 | For |
| SEI | 9,400 | 0 | 0 | 0 | For |
| ProShares | 9,265 | 0 | 0 | 0 | For |
| DWS | 8,323 | 0 | 0 | 0 | For |
| Principal | 6,521 | 0 | 0 | 0 | For |
| State Street | 3,343 | 0 | 0 | 0 | For |
| Calvert | 3,311 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,330 | 0 | 0 | 0 | For |
| Morgan Stanley | 1,882 | 0 | 0 | 0 | For |
Showing the 25 largest of 30 asset managers. All 30 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 54,675,954 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 4.48% |
| 2 | BlackRock | 1.91% |
| 3 | Fidelity | 1.50% |
| 4 | Charles Schwab | 0.60% |
| 5 | Voya | 0.37% |
| 6 | Equitable | 0.32% |
| 7 | QUANTITATIVE MASTER SERIES LLC | 0.14% |
| 8 | Lincoln Financial | 0.07% |
| 9 | Northern Trust | 0.04% |
| 10 | Bridge Builder Trust | 0.04% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Chescapmanager LLC | 3.11% |
| 2 | DISCIPLINED GROWTH INVESTORS INC /MN | 2.93% |
| 3 | BlackRock | 2.83% |
| 4 | FARALLON CAPITAL MANAGEMENT LLC | 2.04% |
| 5 | STIFEL NICOLAUS & CO INC \MO\ | 1.55% |
| 6 | Two Sigma | 1.37% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 1.31% |
| 8 | State Street | 1.23% |
| 9 | Renaissance | 0.62% |
| 10 | Charles Schwab | 0.60% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Vifor (International) Ltd | 7,396,770 | 13.53% | Proxy statement (DEF 14A), table as of April 22, 2024 |
| Blackrock, Inc. | 3,554,258 | 6.50% | Proxy statement (DEF 14A), table as of April 22, 2024 |
| The Vanguard Group | 2,631,067 | 4.81% | Schedule 13G, filed February 13, 2024 |
| Renaissance Technologies | 1,332,478 | 2.44% | Form 13F, quarter ended March 31, 2024 |
| Geode Capital | 1,021,599 | 1.87% | Form 13F, quarter ended March 31, 2024 |
| State Street | 1,002,954 | 1.83% | Form 13F, quarter ended March 31, 2024 |
| Christopher Posner | 674,599 | 1.23% | Proxy statement (DEF 14A), table as of April 22, 2024 |
| Millennium Management | 661,834 | 1.21% | Form 13F, quarter ended March 31, 2024 |
| Joana Goncalves, M.D. | 419,055 | 0.77% | Proxy statement (DEF 14A), table as of April 22, 2024 |
| Northern Trust | 390,807 | 0.71% | Form 13F, quarter ended March 31, 2024 |
Percentages above are of 54,675,954 shares outstanding, as reported by CARA THERAPEUTICS INC. on its Form 10-Q dated May 9, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At CARA THERAPEUTICS INC.'s shareholder meeting held June 4, 2024, in the 2023-2024 proxy season, 120 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 632 separate fund positions. On the most widely held item on that ballot — Approval of, on a non-binding, advisory basis, the compensation of the Company's named… — CARA THERAPEUTICS INC.'s filing reports the proposal as approved, with 60% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: CARA THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 7, 2024.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from CARA THERAPEUTICS INC.’s 10-Q dated May 9, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
CARA THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2025-2026.
Proxy Votes Now, “CARA THERAPEUTICS (TVRD) 2024 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/cara-therapeutics-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.